An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
出版年份 2020 全文链接
标题
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
作者
关键词
-
出版物
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-17
DOI
10.1007/s40261-020-00922-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
- (2019) Arielle G. Bensimon et al. JOURNAL OF MEDICAL ECONOMICS
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of costs associated with adverse events in patients with cancer
- (2018) William Wong et al. PLoS One
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Adjuvant Melanoma Therapy — Head-Spinning Progress
- (2017) Lynn M. Schuchter NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- (2016) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- State-Transition Modeling
- (2012) Uwe Siebert et al. MEDICAL DECISION MAKING
- Model Transparency and Validation
- (2012) David M. Eddy et al. MEDICAL DECISION MAKING
- U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma
- (2012) T. M. Herndon et al. ONCOLOGIST
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Health Care Costs for Patients With Cancer at the End of Life
- (2012) Benjamin Chastek et al. Journal of Oncology Practice
- Economic Burden of Melanoma in the Elderly Population
- (2010) Anne M. Seidler et al. ARCHIVES OF DERMATOLOGY
- Societal preference values for advanced melanoma health states in the United Kingdom and Australia
- (2009) K M Beusterien et al. BRITISH JOURNAL OF CANCER
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started